200 related articles for article (PubMed ID: 37725576)
41. Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23).
Hiwatari M; Ono R; Taki T; Hishiya A; Ishii E; Kitamura T; Hayashi Y; Nosaka T
Leukemia; 2008 Dec; 22(12):2279-80. PubMed ID: 18548106
[No Abstract] [Full Text] [Related]
42. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
Shah S; Loghavi S; Garcia-Manero G; Khoury JD
J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
[TBL] [Abstract][Full Text] [Related]
43. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
Boissel N; Chevallier P; Doronin V; Griskevicius L; Maschan A; McCloskey J; Rambaldi A; Rossi G; Sokolov A; Wartiovaara-Kautto U; Oprea C; Abbadessa G; Gosselin A; Macé S; Thomas X
Cancer Med; 2022 Mar; 11(5):1292-1298. PubMed ID: 35106962
[TBL] [Abstract][Full Text] [Related]
44. Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan.
Halahleh K; Muradi I; Khalil MZ; Halahleh L; Sughayer M; Kamal N; Sultan I; Alrabi K
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e411-e419. PubMed ID: 37730482
[TBL] [Abstract][Full Text] [Related]
45. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Grunewald S; Klug LR; Mühlenberg T; Lategahn J; Falkenhorst J; Town A; Ehrt C; Wardelmann E; Hartmann W; Schildhaus HU; Treckmann J; Fletcher JA; Jung S; Czodrowski P; Miller S; Schmidt-Kittler O; Rauh D; Heinrich MC; Bauer S
Cancer Discov; 2021 Jan; 11(1):108-125. PubMed ID: 32972961
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
47. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
48. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
49. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
50. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
52. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.
Callens C; Baleydier F; Lengline E; Ben Abdelali R; Petit A; Villarese P; Cieslak A; Minard-Colin V; Rullier A; Moreau A; Baruchel A; Schmitt C; Asnafi V; Bertrand Y; Macintyre E
J Clin Oncol; 2012 Jun; 30(16):1966-73. PubMed ID: 22547598
[TBL] [Abstract][Full Text] [Related]
53. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
[TBL] [Abstract][Full Text] [Related]
54. T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.
Cordo' V; van der Zwet JCG; Canté-Barrett K; Pieters R; Meijerink JPP
Blood Cancer Discov; 2021 Jan; 2(1):19-31. PubMed ID: 34661151
[TBL] [Abstract][Full Text] [Related]
55. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
[TBL] [Abstract][Full Text] [Related]
56. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
57. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract][Full Text] [Related]
58. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
59. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
60. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
